Sarcoma patients and their families are invited to participate in an interactive panel discussion and have their questions answered by OHSU physicians and surgeons who focus on the cancer, which...
In a study that kept in touch with more than 500 women cancer survivors for an average of six years, nearly half continued to experience chemotherapy-induced peripheral neuropathy and a heightened...
Men with prostate cancer became more vulnerable to falls if they used androgen deprivation therapy, and the heightened risk of falling persisted for more than a year after ending therapy, a study...
In 1997, Oregon became the first state to make it legal for terminally ill patients to self-administer a prescription to hasten death. A review of 991 cases of lethal self-medication through...
At the end of life, people in Oregon are more likely to have their care wishes honored, less likely to be hospitalized and more likely to use home hospice services compared with people in...
The depth of remission achieved with the targeted therapy imatinib (Gleevec) raises a tough new question for some leukemia patients: is it ever safe to stop taking the breakthrough drug developed at...
The OHSU Knight Cancer Institute’s "Cancer translated" blog explores new findings, ideas and debates in cancer medicine, from basic biology, to clinical trials, to prevention, survivorship and...
McKenna, an incredibly optimistic 11-year-old, has had 16 surgeries and continues to cope with the after-effects of brain cancer. Sarah’s doctors have called her recovery from aggressive...
Unlike the other major causes of cancer mortality, pancreatic cancer is increasing in both incidence and number of deaths each year. Despite improvements in early detection and therapy that have...
Prices of older cancer drugs are rising much more steeply than those of newer drugs, according to a study co-authored by an OHSU oncologist. Using Medicare data available for Part B, the...